Literature DB >> 28921316

The clinical pharmacology of remifentanil: a brief review.

Talmage D Egan1.   

Abstract

Because it is still in its clinical infancy, it is difficult to predict with confidence exactly what role remifentanil will ultimately play in the delivery of anesthesia (and in other settings). It is clear, however, that remifentanil is a new pharmacologic tool with exciting potential that was not possible with the longer-acting opioids. On the basis of its familiar, fentanyl-like pharmacodynamic behavior and its short-acting pharmacokinetic profile, remifentanil may well be advantageous in a variety of settings in which profound opioid effect with subsequent rapid return of spontaneous ventilation and consciousness is desirable. Ongoing research and wide-spread clinical use will be required before the theoretical advantages associated with a short-acting opioid can be fully explored and confirmed.

Entities:  

Keywords:  Pharmacodynamics; Pharmacokinetics; Remifentanil

Year:  1998        PMID: 28921316     DOI: 10.1007/BF02481730

Source DB:  PubMed          Journal:  J Anesth        ISSN: 0913-8668            Impact factor:   2.078


  56 in total

1.  A comparison of remifentanil and alfentanil in patients undergoing major abdominal surgery.

Authors:  J Schüttler; S Albrecht; H Breivik; S Osnes; C Prys-Roberts; K Holder; M Chauvin; J Viby-Mogensen; T Mogensen; I Gustafson; L Lof; D Noronha; A J Kirkham
Journal:  Anaesthesia       Date:  1997-04       Impact factor: 6.955

2.  Pharmacokinetics and pharmacodynamics of remifentanil in persons with renal failure compared with healthy volunteers.

Authors:  J F Hoke; D Shlugman; M Dershwitz; P Michałowski; S Malthouse-Dufore; P M Connors; D Martel; C E Rosow; K T Muir; N Rubin; P S Glass
Journal:  Anesthesiology       Date:  1997-09       Impact factor: 7.892

3.  Awareness during total intravenous anaesthesia with propofol and remifentanil.

Authors:  A J Ogilvy
Journal:  Anaesthesia       Date:  1998-03       Impact factor: 6.955

4.  Severe bradycardia after remifentanil.

Authors:  G DeSouza; M C Lewis; M F TerRiet
Journal:  Anesthesiology       Date:  1997-10       Impact factor: 7.892

5.  Reduction of isoflurane minimal alveolar concentration by remifentanil.

Authors:  E Lang; A Kapila; D Shlugman; J F Hoke; P S Sebel; P S Glass
Journal:  Anesthesiology       Date:  1996-10       Impact factor: 7.892

6.  Remifentanil and propofol combination for awake craniotomy: case report with pharmacokinetic simulations.

Authors:  K B Johnson; T D Egan
Journal:  J Neurosurg Anesthesiol       Date:  1998-01       Impact factor: 3.956

7.  Naloxone-induced and spontaneous reversal of depressed ventilatory responses to hypoxia during and after continuous infusion of remifentanil or alfentanil.

Authors:  H M Amin; A M Sopchak; B F Esposito; L G Henson; R L Batenhorst; A W Fox; E M Camporesi
Journal:  J Pharmacol Exp Ther       Date:  1995-07       Impact factor: 4.030

8.  Anesthetic potency of remifentanil in dogs.

Authors:  L G Michelsen; M Salmenperä; C C Hug; F Szlam; D VanderMeer
Journal:  Anesthesiology       Date:  1996-04       Impact factor: 7.892

9.  Pharmacokinetics and pharmacodynamics of remifentanil in volunteer subjects with severe liver disease.

Authors:  M Dershwitz; J F Hoke; C E Rosow; P Michałowski; P M Connors; K T Muir; J L Dienstag
Journal:  Anesthesiology       Date:  1996-04       Impact factor: 7.892

10.  Preliminary pharmacokinetics and pharmacodynamics of an ultra-short-acting opioid: remifentanil (GI87084B).

Authors:  P S Glass; D Hardman; Y Kamiyama; T J Quill; G Marton; K H Donn; C M Grosse; D Hermann
Journal:  Anesth Analg       Date:  1993-11       Impact factor: 5.108

View more
  4 in total

1.  Necessity and risks of arterial blood sampling in healthy volunteer studies.

Authors:  Bruno Georg Oertel; Johannes Vermehren; Michael Zimmermann; Thomas Tao Huynh; Alexandra Doehring; Nerea Ferreiros; Stephan Senzel; Thomas Schmitz-Rixen; Matthias Erbe; Gerd Geisslinger; Sebastian Harder; Martin S Angst; Jörn Lötsch
Journal:  Clin Pharmacokinet       Date:  2012-10-01       Impact factor: 6.447

2.  Global sensitivity analysis in physiologically-based pharmacokinetic/pharmacodynamic models of inhaled and opioids anesthetics and its application to generate virtual populations.

Authors:  Frank Sánchez Restrepo; Alher Mauricio Hernández Valdivieso
Journal:  J Pharmacokinet Pharmacodyn       Date:  2022-05-26       Impact factor: 2.410

3.  A comparison of risk of hypotension using standard doses of remifentanil versus dexmedetomidine infusions in adult patients undergoing surgery under general anaesthesia at the Aga Khan University Hospital, Nairobi.

Authors:  Maxine Onyango Okello; Vitalis Mung'ayi; Rodney Adam; Jimmie Kabugi
Journal:  Afr Health Sci       Date:  2018-12       Impact factor: 0.927

4.  Mobitz Type II Atrioventricular Block Followed by Remifentanil in a Patient with Severe Aortic Stenosis.

Authors:  Mehryar Taghavi Gilani; Majid Razavi
Journal:  Case Rep Anesthesiol       Date:  2013-04-03
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.